SrasV1, Main, Exploration, bibRecord, 003B21

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Identifieur interne : 003B21 ( Main/Exploration ); précédent : 003B20; suivant : 003B22

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Auteurs : Masahiro Ikejiri [Japon] ; Masayuki Saijo [Japon] ; Shigeru Morikawa [Japon] ; Shuetsu Fukushi [Japon] ; Tetsuya Mizutani [Japon] ; Ichiro Kurane [Japon] ; Tokumi Maruyama [Japon]

Source :

Bioorganic & medicinal chemistry letters : (Print) [ 0960-894X ] ; 2007.

RBID : Pascal:07-0465126

Descripteurs français

KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (synthèse chimique), Cellules Vero, Chimie pharmaceutique (), Concentration inhibitrice 50, Conception de médicament, Conformation moléculaire, Modèles chimiques, Nucléosides (pharmacologie), Nucléosides (synthèse chimique), Purines (), Relation dose-effet des médicaments, Syndrome respiratoire aigu sévère (traitement médicamenteux), Virus du SRAS (métabolisme), Études d'évaluation comme sujet.
MESH :
- métabolisme : Virus du SRAS.
- pharmacologie : Antiviraux, Nucléosides.
- synthèse chimique : Antiviraux, Nucléosides.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
Pascal (Inist)
- Animaux, Cellules Vero, Chimie pharmaceutique, Concentration inhibitrice 50, Conception de médicament, Conformation moléculaire, Modèles chimiques, Purines, Relation dose-effet des médicaments, Synthèse chimique, Relation structure activité, Analogue nucléoside, Antiviral, Virus syndrome respiratoire aigu sévère, Purine nucléoside, In vitro, Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6-chloro), Cyclobutane-1,2-diméthanol dérivé, 1,2,4-Triazole dérivé, Études d'évaluation comme sujet.

English descriptors

KwdEn :
- Animals, Antiviral, Antiviral Agents (chemical synthesis), Antiviral Agents (pharmacology), Chemical synthesis, Chemistry, Pharmaceutical (methods), Chlorocebus aethiops, Dose-Response Relationship, Drug, Drug Design, Evaluation Studies as Topic, In vitro, Inhibitory Concentration 50, Models, Chemical, Molecular Conformation, Nucleoside analog, Nucleosides (chemical synthesis), Nucleosides (pharmacology), Purine nucleoside, Purines (chemistry), SARS Virus (metabolism), Severe Acute Respiratory Syndrome (drug therapy), Severe acute respiratory syndrome virus, Structure activity relation, Vero Cells.
MESH :
- chemical , chemical synthesis : Antiviral Agents, Nucleosides.
- chemical , chemistry : Purines.
- chemical , pharmacology : Antiviral Agents, Nucleosides.
- drug therapy : Severe Acute Respiratory Syndrome.
- metabolism : SARS Virus.
- methods : Chemistry, Pharmaceutical.
- Animals, Chlorocebus aethiops, Dose-Response Relationship, Drug, Drug Design, Evaluation Studies as Topic, Inhibitory Concentration 50, Models, Chemical, Molecular Conformation, Vero Cells.

Abstract

Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents</title>
<author><name sortKey="Ikejiri, Masahiro" sort="Ikejiri, Masahiro" uniqKey="Ikejiri M" first="Masahiro" last="Ikejiri">Masahiro Ikejiri</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sanuki, Kagawa 769-2193</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maruyama, Tokumi" sort="Maruyama, Tokumi" uniqKey="Maruyama T" first="Tokumi" last="Maruyama">Tokumi Maruyama</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sanuki, Kagawa 769-2193</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0465126</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0465126 INIST</idno>
<idno type="RBID">Pascal:07-0465126</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000345</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000644</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000329</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000329</idno>
<idno type="wicri:doubleKey">0960-894X:2007:Ikejiri M:synthesis:and:biological</idno>
<idno type="wicri:Area/Main/Merge">003C76</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17336519</idno>
<idno type="wicri:Area/PubMed/Corpus">001E80</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E80</idno>
<idno type="wicri:Area/PubMed/Curation">001E80</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E80</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001C75</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C75</idno>
<idno type="wicri:Area/Ncbi/Merge">001891</idno>
<idno type="wicri:Area/Ncbi/Curation">001891</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001891</idno>
<idno type="wicri:doubleKey">0960-894X:2007:Ikejiri M:synthesis:and:biological</idno>
<idno type="wicri:Area/Main/Merge">003699</idno>
<idno type="wicri:Area/Main/Curation">003B21</idno>
<idno type="wicri:Area/Main/Exploration">003B21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents</title>
<author><name sortKey="Ikejiri, Masahiro" sort="Ikejiri, Masahiro" uniqKey="Ikejiri M" first="Masahiro" last="Ikejiri">Masahiro Ikejiri</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sanuki, Kagawa 769-2193</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Maruyama, Tokumi" sort="Maruyama, Tokumi" uniqKey="Maruyama T" first="Tokumi" last="Maruyama">Tokumi Maruyama</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sanuki, Kagawa 769-2193</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title>
<idno type="ISSN">0960-894X</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title>
<idno type="ISSN">0960-894X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral</term>
<term>Antiviral Agents (chemical synthesis)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chemical synthesis</term>
<term>Chemistry, Pharmaceutical (methods)</term>
<term>Chlorocebus aethiops</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Design</term>
<term>Evaluation Studies as Topic</term>
<term>In vitro</term>
<term>Inhibitory Concentration 50</term>
<term>Models, Chemical</term>
<term>Molecular Conformation</term>
<term>Nucleoside analog</term>
<term>Nucleosides (chemical synthesis)</term>
<term>Nucleosides (pharmacology)</term>
<term>Purine nucleoside</term>
<term>Purines (chemistry)</term>
<term>SARS Virus (metabolism)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (synthèse chimique)</term>
<term>Cellules Vero</term>
<term>Chimie pharmaceutique ()</term>
<term>Concentration inhibitrice 50</term>
<term>Conception de médicament</term>
<term>Conformation moléculaire</term>
<term>Modèles chimiques</term>
<term>Nucléosides (pharmacologie)</term>
<term>Nucléosides (synthèse chimique)</term>
<term>Purines ()</term>
<term>Relation dose-effet des médicaments</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Virus du SRAS (métabolisme)</term>
<term>Études d'évaluation comme sujet</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Antiviral Agents</term>
<term>Nucleosides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Purines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Nucleosides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemistry, Pharmaceutical</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Nucléosides</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antiviraux</term>
<term>Nucléosides</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Design</term>
<term>Evaluation Studies as Topic</term>
<term>Inhibitory Concentration 50</term>
<term>Models, Chemical</term>
<term>Molecular Conformation</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Cellules Vero</term>
<term>Chimie pharmaceutique</term>
<term>Concentration inhibitrice 50</term>
<term>Conception de médicament</term>
<term>Conformation moléculaire</term>
<term>Modèles chimiques</term>
<term>Purines</term>
<term>Relation dose-effet des médicaments</term>
<term>Synthèse chimique</term>
<term>Relation structure activité</term>
<term>Analogue nucléoside</term>
<term>Antiviral</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Purine nucléoside</term>
<term>In vitro</term>
<term>Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6-chloro)</term>
<term>Cyclobutane-1,2-diméthanol dérivé</term>
<term>1,2,4-Triazole dérivé</term>
<term>Études d'évaluation comme sujet</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><noRegion><name sortKey="Ikejiri, Masahiro" sort="Ikejiri, Masahiro" uniqKey="Ikejiri M" first="Masahiro" last="Ikejiri">Masahiro Ikejiri</name>
</noRegion>
<name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<name sortKey="Maruyama, Tokumi" sort="Maruyama, Tokumi" uniqKey="Maruyama T" first="Tokumi" last="Maruyama">Tokumi Maruyama</name>
<name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B21 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B21 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:07-0465126
   |texte=   Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.